Fri, Dec 26, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Zenith believes good CTAs offer protection from market volatility

Thursday, April 11, 2013

Beverly Chandler, Opalesque London: Zenith Investment Partners has just released its 2013 CTA / Macro Sector findings. Daniel Liptak, Head of Alternatives said: "With the performance of many CTAs struggling over the last 18 – 24 months we believe that it is timely to consider the function and utility such funds can make to a portfolio."

Zenith believes that CTAs are an important strategy that should be considered as part of a diversified portfolio, particularly as over the medium term CTAs have historically provided an offset at times of acute equity market stress. "This observation is the likely cause of many investors believing that CTAs are long volatility, when in fact they are long gamma (they become more exposed to a trend as it becomes more pronounced, regardless of direction). Being long gamma allows this investment style to take advantages of being a liquidity provider in markets undergoing forced sales. Investors in CTAs need to understand that not all market conditions are conducive to positive returns and, indeed on a standalone basis CTAs can disappoint" Zenith says.

While Zenith believes that medium term CTAs can act as an offset in dislocated equity markets, they are hesitant to class CTAs as being un-correlated to equity markets, believing that they are on the whole non-correlated to equities. "This is an important observation, as this suggests that the returns from CTAs are independent......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its